Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Farinha (Coimbra, Portugal), A. Cunha (Coimbra, Portugal), F. Costa (Coimbra, Portugal). Monitoring disease progression in severe Alpha1 antitrypsin deficiency. 188

Member's Comments

No comment yet.

Related content which might interest you: Alpha-1 antitrypsin deficiency – a potentially fatal disease Source: International Congress 2017 – Rare and common genetic variants of common and rare airway diseases Year: 2017 Screening of chronic liver disease by transient elastography in patients with lung disease associated with alpha-1 antitrypsin deficiency. Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 Alpha-1 antitrypsin deficiency severity and the risk of COVID-19 Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19 Year: 2021 The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes Source: Eur Respir J, 56 (6) 2001441; 10.1183/13993003.01441-2020 Year: 2020 Screening for alpha-1 antitrypsin deficiency in Polish lung or liver disease patients Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011 Clinical features of alpha one antitrypsin deficiency in COPD Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Lung function in relation to emphysema development in alpha-1 antitrypsin deficiency Source: International Congress 2019 – Insights into physiological diagnostic services Year: 2019 Degree of knowledge among physicians about the diagnosis and treatment of alpha-1 antitrypsin deficiency Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Gene expression network in PiZZ Alpha1 Antitrypsin Deficiency and its relationship with the severity of lung disease Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases Year: 2017 Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Oxidative stress in serum of patients with alpha-1 antitrypsin deficiency Source: Annual Congress 2013 –New perspectives of lung function assessment in children Year: 2013 Exercise intolerance and lung emphysema in alpha-1 antitrypsin deficiency (AATD) Source: Annual Congress 2010 - Exercise in COPD Year: 2010 Long-term evolution of individuals with alpha1 antitrypsin deficiency from the Spanish registry Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Smoke exposure as a determinant of autoantibody titre in alpha 1-antitrypsin deficiency and COPD Source: Eur Respir J 2011; 37: 32-38 Year: 2011 Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe dyspnea Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 Specific airway resistance as a marker of early disease in alpha-1 antitrypsin deficiency Source: International Congress 2015 – Lung function: exploring the boundaries of the respiratory system Year: 2015 Population pharmacokinetics of A1-PI in patients with Alpha-1 antitrypsin deficiency Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Mechanisms of liver disease in AATD Source: Eur Respir Monogr 2019; 85: 93-104 Year: 2019